Decoy Therapeutics Inc.
NASDAQDecoy Therapeutics heads into a critical two-day window with a fresh earnings miss on the books and a major lock-up agreement expiring on May 11. The most urgent catalyst is the lock-up. Over one million common shares — held by officers, directors, and related parties — come free from their 180-day lock-up restriction on Monday, May 11. That follows directly on the heels of Q1…
Snapshot as of 9 May 2026
Decoy Therapeutics heads into a critical two-day window with a fresh earnings miss on the books and a major lock-up agreement expiring on May 11. The most urgent catalyst is the lock-up. Over one million common shares…
Decoy Therapeutics approaches its May 12 quarterly print with short sellers visibly retreating — yet the cost of that retreat is still being paid by anyone remaining on the short side. The lending market tells a story…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for DCOY — free to start on ORTEX.
Sign up for free →Open DCOY on ORTEX